Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Adma Biologics (NQ: ADMA )

9.210 +0.150 (+1.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,629,093
Open 9.070
Bid (Size) 9.200 (1)
Ask (Size) 9.300 (50)
Prev. Close 9.060
Today's Range 8.910 - 9.310
52wk Range 3.060 - 9.330
Shares Outstanding 196,357,149
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday
Via Benzinga

Performance

YTD
+102.42%
+102.42%
1 Month
+52.48%
+52.48%
3 Month
+74.43%
+74.43%
6 Month
+131.99%
+131.99%
1 Year
+130.83%
+130.83%

More News

Read More
ADMA Biologics Analysts Increase Their Forecasts After Upbeat Results
Via Benzinga
A Closer Look at 6 Analyst Recommendations For ADMA Biologics
Via Benzinga
ADMA Stock Earnings: ADMA Biologics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
Chart Of The Day: ADMA Biologics - Hitting New Highs
Via Talk Markets
ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024
From ADMA Biologics, Inc.
Via GlobeNewswire
Forecasting The Future: 4 Analyst Projections For ADMA Biologics
Via Benzinga
Recap: ADMA Biologics Q4 Earnings
Via Benzinga
ADMA Biologics Announces FDA Approvals of Extended Room Temperature Storage Conditions for ASCENIV™ & BIVIGAM®
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces CFO Transition
From ADMA Biologics, Inc.
Via GlobeNewswire
Earnings Preview For ADMA Biologics
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For ADMA Biologics
Via Benzinga
ADMA Biologics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Successfully Implements Innovative AI Program, Named ADMAlytics
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces Preliminary Fourth Quarter 2023 Revenue and Provides Business Update
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces $135 Million Non-Dilutive Refinancing of Credit Facilities with Ares Management
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics Announces FDA Approval for BIVIGAM® in the Pediatric Patient Setting for Those 2 Years of Age and Older
From ADMA Biologics, Inc.
Via GlobeNewswire
Why Adma Biologics Stock Crushed the Market on Friday
Via The Motley Fool
ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
From ADMA Biologics, Inc.
Via GlobeNewswire
Why Adma Biologics Was Trouncing the Market Today
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.